Eisai Gives Takeover-Blocking Authority To Outside Directors
This article was originally published in PharmAsia News
Executive Summary
Eisai has established a committee of outside directors to be ready to take protective action if the company becomes a takeover target by another company. The directors themselves proposed the program and have been given the charge to decide for themselves whether to implement it. Normally, company executives make an anti-takeover effort, but they have been criticized for protecting their own interests instead of that of the company. More than half of Eisai's board members are outside directors given independence to act so the decision would not be left to people close to the founding family or officials with major business connections. (Click here for more - a subscription may be required
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.